English
Home > Products > CAS:57-83-0

China CAS:57-83-0 Manufacturer

We are commitment to offer the competitive price ,outstanding products quality, as well as fast delivery for CAS:57-83-0, With our rules of " small business track record, partner trust and mutual benefit", welcome all of you to definitely work together , expand with each other.
CAS:57-83-0, Our aim is to help customers realize their goals. We have been making great efforts to achieve this win-win situation and sincerely welcome you to join us. In a word, when you choose us, you choose a perfect life. Welcome to visit our factory and welcome your order! For further inquiries, remember to do not hesitate to contact us.

Related Products

Hot Products

  • Finasteride

    Finasteride

    Finasteride has EP, USP, CP, IP, JP specifications. CEP available, FDA, PMDA and GMP approved.

    CAS:98319-26-7

  • Budesonide

    Budesonide

    Budesonide has USP, EP specifications. CEP, GMP and FDA approved.

    CAS:51333-22-3

  • Methylprednisolone

    Methylprednisolone

    Methylprednisolone has USP, EP, IP, JP and KP specifications. DMF and WC available.

    CAS:83-43-2

  • Eslicarbazepine Acetate

    Eslicarbazepine Acetate

    Eslicarbazepine Acetate has In-house specification. DMF approved.

    CAS:236395-14-5

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide is an intermediate of Dutasteride.

    CAS:98319-24-5

  • Related Blog
  • Reviews

  • CPHI & PMEC China 2024 Ended Successfully

    From June 19 to 21, the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2024), organized by Informa Markets and China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products and co-organized by Shanghai Bohua International Exhibition Co., LTD., was held in Shanghai. Nearly 3,500 well-known exhibitors at home and abroad gathered in Shanghai New International Expo Center (Pudong), attracting more than 60,000 professional buyers from more than 150 countries and regions, and a total of more than 90,000 industry colleagues to participate in the event.

  • Welcome to Xi'an API 2024

    The 91th API China & PHARMEX & PHARMPACK & SINOPHEX will be held at National Exhibition and Convention Center (Xi’an) from October 16 to 18, our booth number is 3A08.

  • Welcome to IPhEB Russia 2025

    ​IPhEB Russia 2025 will be held at EXPOFORUM Convention and Exhibition Centre from April 08-10,2025, our booth number is 320.

  • CPHI China 2025 | Looking forward to meeting you!

    CPHI China will be staged at Shanghai New International Expo Center on June 24-26, 2025 together with ICSE & PMEC China,our booth number is W1G20(b).

  • Join Us at Booth B9023 for Pharmtech & Ingredients 2025

    ​Pharmtech & ingredients 2025 will be held at International Exhibition Centre “Crocus Expo” from November 25-28, our booth number is B9023.

  • What Is the Intermediates Category and Why Does It Matter in Modern Pharmaceutical Manufacturing

    In today’s highly specialized chemical industry, the Intermediates Category plays a critical role in bridging raw materials and final active pharmaceutical ingredients. Companies like Humanwell are deeply involved in the development and supply of high-quality intermediates, ensuring efficiency, safety, and scalability across pharmaceutical production chains.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept